Defining outcomes for beta cell replacement therapy: a work in progress

Diabetologia. 2018 Jun;61(6):1273-1276. doi: 10.1007/s00125-018-4588-0. Epub 2018 Mar 6.

Abstract

Defined outcomes for beta cell replacement therapy in the treatment of diabetes are critically needed. Progress towards the clinical acceptance of pancreas and islet transplantation has been hampered by the lack of clear definitions of functional and efficacy outcomes, as well as a lack of consistently applied glycaemic control metrics, together with poor alignment with the field of artificial insulin delivery/artificial pancreas development. To address this problem, the International Pancreas & Islet Transplant Association (IPITA) collaborated with the European Pancreas and Islet Transplant Association (EPITA) to develop a consensus for a joint statement on the definition of function and failure of beta cell replacement therapies, which is summarised in this commentary.

Keywords: Islet transplantation; Outcomes; Pancreas transplantation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Glucose / analysis
  • C-Peptide / analysis
  • Europe
  • Glycated Hemoglobin / analysis
  • Guidelines as Topic
  • Humans
  • Hypoglycemia / diagnosis
  • International Cooperation
  • Islets of Langerhans Transplantation / methods*
  • Islets of Langerhans Transplantation / standards*
  • Pancreas Transplantation / methods*
  • Pancreas Transplantation / standards*
  • Patient Satisfaction
  • Societies, Medical
  • Treatment Outcome

Substances

  • Blood Glucose
  • C-Peptide
  • Glycated Hemoglobin A
  • hemoglobin A1c protein, human